Aeva and ZF Bring First FMCW LiDAR to Automotive Production
8.9.2020 16:00:00 EEST | Business Wire | Press release
Aeva, a leader in next generation sensing and perception systems, and ZF, a top global automotive Tier-1 supplier, are partnering to bring the world’s first Frequency Modulated Continuous Wave (FMCW) LiDAR to the automotive market. The partnership — Aeva's expertise in FMCW LiDAR technology combined with ZF's experience in industrialization of automotive grade sensors — represents a key commitment to accelerate mass production of safe and scalable 4D LiDAR technology for autonomous driving applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005368/en/
Aeva and ZF partner for production of first automotive grade FMCW LiDAR for automated driving. (Photo: Business Wire)
“From early on we have believed in building an ecosystem of the world’s most capable partners across the industry and this partnership is one part of that plan. ZF’s capability as one of the largest Tier-1s globally with expertise in automotive scale production of sensing systems is a key step to accelerating the introduction of safe and scalable autonomous vehicles,” said Soroush Salehian, Co-Founder of Aeva. “The industry is at the cusp of deploying the next generation of sensing to realize the adoption of highly automated and autonomous cars and we believe Aeva’s 4D LiDAR will be an indispensable part of this next chapter.”
About the Partnership
Aeva and ZF aim to bring the first automotive grade 4D LiDAR to market for autonomous driving applications. The partnership strengthens the parties’ collaboration by leveraging Aeva’s unique expertise in FMCW LiDAR and perception technology together with ZF’s expertise as a leading automotive supplier, autonomous systems provider, and market leader in smart cameras and the corresponding production know-how. The final system is targeted as a key solution for autonomous driving applications including established truck and OEM manufacturers as well as leading mobility as a service customers.
“LiDAR is a key technology for systems and sensing in the area of highly automated and autonomous driving. Aeva’s unique FMCW technology combines long range performance and direct velocity measurements, making it the right choice for autonomous driving applications. We have seen that different markets require different solutions. For L2+/L3 systems a package and cost optimized Lidar is crucial. For applications which feature L4 and further solutions, the focus lies on range and direct velocity measurement, as edge performance is key for the virtual driver software stack.
Aeva’s FMCW technology approach perfectly meets all the stringent requirements for autonomous operations in trucks and robo-service vehicles. We look forward to bring the world’s first FMCW LiDAR to an automotive grade level and scale production, where ZF can rely on a long-lasting production experience in optical sensors. ‘Automotive Grade’ will become a quality seal, necessary for a solid business model of all autonomous vehicle software stack providers,” said Torsten Gollewski, Executive Vice President Autonomous Mobility Solutions at ZF.
As part of the partnership, Aeva will be responsible for the FMCW LiDAR core sensing functionality, performance and algorithms and ZF will be responsible for industrialization of the automotive grade sensing system that meets all automotive requirements.
What makes Aeva’s 4D LiDAR unique?
Aeva’s FMCW technology is designed to meet the challenging performance and the manufacturability requirements for adoption of LiDAR in autonomous vehicles.
Unlike other LiDAR technologies, Aeva’s 4D LiDAR-on-chip uses a continuous laser beam to measure the change in frequency of the waveform as it reflects off of an object. This allows it to detect an object’s range and instant velocity simultaneously beyond 300 meters at high accuracy. Aeva’s 4D LiDAR is also completely free of interference from other sensors or sunlight and it operates at only fractions of the optical power typically required to achieve long range performance. All of which are critical hurdles that have previously slowed the broad adoption of automotive LiDAR.
Aeva’s technology also differs from other FMCW approaches in its unique ability to break the dependency between maximum range and points density. Aeva’s 4D LiDAR integrates multiple beams on a chip that is produced at silicon wafer scale. Each beam is uniquely capable of measuring multiple millions of points per second at maximum range providing unprecedented data fidelity and significantly enhancing the factor of safety for self-driving cars.
About Aeva
Aeva was founded in 2017 by Soroush Salehian, and Mina Rezk -- previously engineering leaders at Apple & Nikon. Headquartered in Mountain View, California, Aeva is building the next-generation of sensing and perception for autonomous vehicles that is safe, simple, and scalable. Aeva is backed by Volkswagen’s Porsche SE, Lux Capital and Canaan Partners, amongst others. For more information, visit www.aeva.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005368/en/
Contact information
Michelle Chang
Press@aeva.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 15:23:00 EEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR) patient populations, treatment settings, and manifestations of disease. Additionally, the data expand the potential application of RNAi to uncontrolled hypertension, the world’s leading cause of cardiovascular disease. “With the power of our RNAi therapeutics platform, we have the potential to make a transformational impact on cardiovascular care,” said Pushkal Garg, M.D., Chief Research and Development Officer at Alnylam. “The data presented at ESC demonstrate the consistency of clinical outcomes achieved by RNAi-powered TTR silencing, reinforcing our conviction in AMVUTTRA as a first-line treatment option for ATTR-CM. With
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202630.8.2026 00:54:00 EEST | Press release
Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon company, in strategic partnership with the Emirates Falconers’ Club, at ADNEC Centre Abu Dhabi. The exhibition runs until 6 September. The falcon, owned
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 01:40:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the total amount of blood in the body. Maintaining controlled hematocrit levels below 45% is the primary treatment goal in PV.1 “For patients living with PV, uncontrolled hematocrit can have serious consequences, including an elevated risk of life-threatening thrombotic events," said Andrew T. Kuykendall, M.D., VERIFY lead investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “Curre
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
